AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NovoCure Ltd Director's Dealing 2025

Jan 6, 2025

31949_dirs_2025-01-06_7f1e7ede-f91a-4d15-a846-529e6f387c10.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2025-01-01

Reporting Person: Brackmann Christoph (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	11200.00	Direct
Restricted Share Units	60277.00	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to buy)	$16.59	2034-11-03	Ordinary Shares (91240.00)		Direct

Footnotes

F1: Represents restricted share units that are scheduled to vest on November 4, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

F2: Options to buy 91,240 ordinary shares will vest in equal installments on each of November 4, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.